# Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

> **NCT05036733** · PHASE4 · COMPLETED · sponsor: **University of Michigan** · enrollment: 15 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT05036733
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036733, "Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05036733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*